{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:01:02Z","timestamp":1788447662182,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Epidermolysis bullosa (EB) comprises inherited mechanobullous dermatoses with considerable morbidity and mortality. While current treatments are symptomatic, a growing number of innovative therapeutic compounds are evaluated in clinical trials. Clinical research in rare diseases like EB, however, faces many challenges, including sample size requirements and recruitment failures. The objective of this study was to determine attitudes of EB patients towards clinical research and trial participation as well as the assessment of contextual motivating and discouraging factors in an effort to support patient-centered RD trial designing.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A 53-items questionnaire was handed over to EB patients (of all types and ages) in contact with the EB House Austria, a designated national center of expertise for EB care. Main categories included level of interest in and personal knowledge about clinical studies, pros\/cons for participation and extent of individual expenses considered acceptable for participation in a clinical study. Descriptive subgroup analysis was calculated with SPSS 20.0 and Microsoft Excel.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Thirty-six individuals (mean age 25.7\u2009years), diagnosed for recessive dystrophic EB (36.1%), EB simplex (33.4%), junctional EB (8.3%), dominant dystrophic EB (2.8%) and acral peeling syndrome (2.8%) participated. Motivation for participation in and the desire to increase personal knowledge about clinical trials were (outmost) high in 57.2 and 66.7%, respectively. Altruism was the major motivating factor, followed by hope that alleviation of the own symptoms can be achieved. The greatest hurdle was travel distance, followed by concerns about possible adverse reactions. Patients diagnosed for severe subgroups (RDEB, JEB) were more impaired by the extent of scheduled invasive investigations and possible adverse reactions of the study medication. Patients with generally milder EB forms and older patients were accepting more frequent outpatient study visits, blood takes, skin biopsies and inpatient admissions in association with trial participation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study provides additional indications to better determine and address attitudes towards clinical research among EB patients as well as guidance to improve clinical trial protocols for patient centricity.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-01443-3","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T07:03:42Z","timestamp":1594364622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Profiling trial burden and patients\u2019 attitudes to improve clinical research in epidermolysis bullosa"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5255-8140","authenticated-orcid":false,"given":"Christine","family":"Prodinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Diem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherina","family":"Ude-Schoder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Pi\u00f1\u00f3n-Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Kitzmueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann W.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Laimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"1443_CR1","doi-asserted-by":"publisher","unstructured":"Has C, Bauer J, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.18921.","DOI":"10.1111\/bjd.18921"},{"issue":"10","key":"1443_CR2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/exd.13668","volume":"28","author":"C Has","year":"2019","unstructured":"Has C, Fischer J. Inherited epidermolysis bullosa: new diagnostics and new clinical phenotypes. Exp Dermatol. 2019;28(10):1146\u201352.","journal-title":"Exp Dermatol"},{"issue":"7","key":"1443_CR3","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1089\/wound.2014.0522","volume":"3","author":"CJ Lewis","year":"2014","unstructured":"Lewis CJ, Mardaryev AN, Sharov AA, Fessing MY, Botchkarev VA. The epigenetic regulation of wound healing. Adv Wound Care (New Rochelle). 2014;3(7):468\u201375.","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"1443_CR4","doi-asserted-by":"crossref","unstructured":"De Rosa L, Latella MC, Secone Seconetti A, et al. Toward Combined Cell and Gene Therapy for Genodermatoses. Cold Spring Harb Perspect Biol. 2020;12(5):a035667.","DOI":"10.1101\/cshperspect.a035667"},{"issue":"10","key":"1443_CR5","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/exd.13979","volume":"28","author":"C Prodinger","year":"2019","unstructured":"Prodinger C, Reichelt J, Bauer JW, Laimer M. Epidermolysis bullosa: advances in research and treatment. Exp Dermatol. 2019;28(10):1176\u201389.","journal-title":"Exp Dermatol"},{"issue":"3","key":"1443_CR6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40291-020-00466-7","volume":"24","author":"C Has","year":"2020","unstructured":"Has C, South A, Uitto J. Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020. Mol Diagn Ther. 2020;24(3):299\u2013309.","journal-title":"Mol Diagn Ther"},{"key":"1443_CR7","unstructured":"Mellerio JE, Uitoo J. Meeting Report: The First Global Congress on Epidermolysis Bullosa, EB2020 London \u2013 Toward Treatment and Cure. J Invest Dermatol. 2020 May 16;S0022-202X(20)31573\u20136."},{"key":"1443_CR8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ajmg.c.31533","volume":"172C","author":"L Abrahamyan","year":"2016","unstructured":"Abrahamyan L, Feldman BM, Tomlinson G, et al. Alternative designs for clinical trials in rare diseases. Am J Med Genet Part C Semin Med Genet. 2016;172C:313\u201331.","journal-title":"Am J Med Genet Part C Semin Med Genet"},{"key":"1443_CR9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13023-018-0931-2","volume":"13","author":"S Day","year":"2018","unstructured":"Day S, Jonker AH, Lau LPL, et al. Recommendations for the design of small population clinical trials. Orphanet J Rare Dis. 2018;13:195.","journal-title":"Orphanet J Rare Dis"},{"key":"1443_CR10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040324","volume":"4","author":"GE Henderson","year":"2007","unstructured":"Henderson GE, Churchill LR, Davis AM, et al. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med. 2007;4:e324.","journal-title":"PLoS Med"},{"key":"1443_CR11","unstructured":"FDA. Digital Health. Available at: https:\/\/www.fda.gov\/MedicalDevices\/DigitalHealth\/default.htm (last accessed 20 Dec 2019)."},{"key":"1443_CR12","volume-title":"Clinical Trial Consent: There Is and App For That","author":"L Strom","year":"2017","unstructured":"Strom L, Mulryne J, Tsang L. Clinical Trial Consent: There Is and App For That. 2017. Available at: https:\/\/www.digitalhealthdownload.com\/2017\/03\/clinical-trial-consent-app (last accessed 20 December 2019)."},{"key":"1443_CR13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2147\/PPA.S104259","volume":"10","author":"JA Sacrist\u00e1n","year":"2016","unstructured":"Sacrist\u00e1n JA, Aguar\u00f3n A, Avenda\u00f1o-Sol\u00e1 C, et al. Patient involvement in clinical research: why, when, and how. Patient Prefer Adherence. 2016;10:631\u201340.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"1443_CR14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/2168479017716715","volume":"52","author":"B Levitan","year":"2018","unstructured":"Levitan B, Getz K, Eisenstein EL, et al. Assessing the financial value of patient engagement: a quantitative approach from CTTI's patient groups and clinical trials project. Ther Innov Regul Sci. 2018;52(2):220\u20139.","journal-title":"Ther Innov Regul Sci"},{"key":"1443_CR15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1472-6963-14-89","volume":"14","author":"JP Domecq","year":"2014","unstructured":"Domecq JP, Prutsky G, Elraiyah T, Wang Z, Nabhan M, Shippee N. Patient engagement in research: a systematic review. BMC Health Serv Res. 2014;14:89.","journal-title":"BMC Health Serv Res"},{"key":"1443_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1162\/152651602317533523","volume":"2","author":"FG Miller","year":"2002","unstructured":"Miller FG, Brody H. What makes placebo-controlled trials unethical? Am J Bioeth. 2002;2:3\u20139.","journal-title":"Am J Bioeth"},{"key":"1443_CR17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1191\/0962280202sm300ra","volume":"11","author":"AJ London","year":"2002","unstructured":"London AJ, Kadane JB. Placebos that harm: sham surgery controls in clinical trials. Stat Methods Med Res. 2002;11:413\u201327.","journal-title":"Stat Methods Med Res"},{"key":"1443_CR18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/15265160601171606","volume":"7","author":"RA Martin","year":"2007","unstructured":"Martin RA, Robert JS. Is risky pediatric research without prospect of direct benefit ever justified? Am J Bioeth. 2007;7:12\u20135.","journal-title":"Am J Bioeth"},{"key":"1443_CR19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/bmj.318.7191.1114","volume":"318","author":"AJ Welton","year":"1999","unstructured":"Welton AJ, Vickers MR, Cooper JA, Meade TW, Marteau TM. Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study. BMJ. 1999;318:1114\u20137.","journal-title":"BMJ"},{"key":"1443_CR20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","volume":"312","author":"DL Sackett","year":"1996","unstructured":"Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71\u20132.","journal-title":"BMJ"},{"issue":"9","key":"1443_CR21","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"28","author":"EF Augustine","year":"2013","unstructured":"Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28(9):1142\u201350.","journal-title":"J Child Neurol"},{"key":"1443_CR22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13023-019-1002-z","volume":"14","author":"CMW Gaasterland","year":"2019","unstructured":"Gaasterland CMW, van der Weide MCJ, Prie-Olthof MJ, et al. The patient\u2019s view on rare disease trial design \u2013 a qualitative study. Orphanet J Rare Dis. 2019;14:31.","journal-title":"Orphanet J Rare Dis"},{"key":"1443_CR23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev-genom-091212-153525","volume":"14","author":"PP Koay","year":"2013","unstructured":"Koay PP, Sharp RR. The role of patient advocacy organizations in shaping genomic science. Annu Rev Genomics Hum Genet. 2013;14:579\u201395.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"1443_CR24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-019-1017-5","volume":"14","author":"AE Mulberg","year":"2019","unstructured":"Mulberg AE, Bucci-Rechtweg C, Giuliano J, et al. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders. Orphanet J Rare Dis. 2019;14:36.","journal-title":"Orphanet J Rare Dis"},{"key":"1443_CR25","first-page":"Mr000013","volume":"2","author":"S Treweek","year":"2018","unstructured":"Treweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018;2:Mr000013.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1443_CR26","doi-asserted-by":"crossref","first-page":"e015276","DOI":"10.1136\/bmjopen-2016-015276","volume":"7","author":"SJ Walters","year":"2017","unstructured":"Walters SJ, Bonacho DAHI, Bortolami O, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the UK Health Technology Assessment Programme. BMJ Open. 2017;7(3):e015276.","journal-title":"BMJ Open"},{"key":"1443_CR27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13063-018-2645-0","volume":"19","author":"RA Crow","year":"2018","unstructured":"Crow RA, Hart KA, McDermott MP, et al. A checklist for clinical trials in rare disease: obstacles and anticipatory actions\u2014lessons learned from the FOR-DMD trial. Trials. 2018;19:291.","journal-title":"Trials"},{"key":"1443_CR28","volume-title":"Guideline on clinical trials in small populations","author":"EMA\/CHMP","year":"2007","unstructured":"EMA\/CHMP. Guideline on clinical trials in small populations. 2007. Available at: www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003615.pdf (last accessed 20 Dec 2019)."},{"issue":"1","key":"1443_CR29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13023-016-0464-5","volume":"11","author":"RD Hilgers","year":"2016","unstructured":"Hilgers RD, Roes K, Stallard N. IDeAl, Asterix and InSPiRe project groups. Directions for new developments on statistical design and analysis of small population group trials. Orphanet J Rare Dis. 2016;11(1):78.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1443_CR30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.drudis.2019.01.005","volume":"24","author":"DA Fonseca","year":"2019","unstructured":"Fonseca DA, Amaral I, Pinto AC, Cotrim MD. Orphan drugs: major development challenges at the clinical stage. Drug Discov Today. 2019;24(3):867\u201372.","journal-title":"Drug Discov Today"},{"key":"1443_CR31","unstructured":"Batten E. Recruiting patients to rare disease clinical trials. 2019. Available at: https:\/\/www.amrc.org.uk\/blog\/recruiting-patients-to-rare-disease-clinical-trials#_ftnref (last accessed at 20 Dec 2019)."},{"key":"1443_CR32","volume-title":"Rare disease patients' participation in research. A Rare Barometer survey","author":"Eurodis","year":"2018","unstructured":"Eurodis. Rare disease patients' participation in research. A Rare Barometer survey. 2018. Available at: http:\/\/download2.eurordis.org.s3.amazonaws.com\/rbv\/2018_02_12_rdd-research-survey-analysis.pdf (last accessed 20 Dec 2019)."},{"key":"1443_CR33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(06)70576-9","volume":"7","author":"EJ Mills","year":"2006","unstructured":"Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006;7:141\u20138.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1443_CR34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197513","volume":"13","author":"Z Zolkipli-Cunningham","year":"2018","unstructured":"Zolkipli-Cunningham Z, Xiao R, Stoddart A, et al. Mitochondrial disease patient motivations and barriers to participate in clinical trials. PLoS One. 2018;13(5):e0197513.","journal-title":"PLoS One"},{"key":"1443_CR35","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.rmed.2009.09.023","volume":"104","author":"BW Kinder","year":"2010","unstructured":"Kinder BW, Sherman AC, Young LR, et al. Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis. Resp Med. 2010;104:578\u201383.","journal-title":"Resp Med"},{"issue":"2","key":"1443_CR36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2307\/3562038","volume":"17","author":"PS Applebaum","year":"1987","unstructured":"Applebaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Center Rep. 1987;17(2):20\u20134.","journal-title":"Hastings Center Rep"},{"key":"1443_CR37","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jamainternmed.2016.6008","volume":"176","author":"TJ Hwang","year":"2016","unstructured":"Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med. 2016;176:1826\u201333.","journal-title":"JAMA Intern Med"},{"key":"1443_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1745-6215-7-9","volume":"7","author":"AM McDonald","year":"2006","unstructured":"McDonald AM, Knight RC, Campbell MK, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006;7:9.","journal-title":"Trials"},{"issue":"1","key":"1443_CR39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/ecc.12184","volume":"24","author":"T Godskesen","year":"2015","unstructured":"Godskesen T, Hansson MG, Nygren P, Nordin K, Kihlbom U. Hope for a cure and altruism are the main motives behind participation in phase 3 clinical trials. Eur J Canc Care. 2015;24(1):133\u201341.","journal-title":"Eur J Canc Care"},{"key":"1443_CR40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/JOP.2013.001039","volume":"9","author":"RF Brown","year":"2013","unstructured":"Brown RF, Cadet DL, Houlihan RH, et al. Perceptions of participation in a phase I, II, or III clinical trial among African American patients with cancer: what do refusers say? J Oncol Pract. 2013;9:287\u201393.","journal-title":"J Oncol Pract"},{"key":"1443_CR41","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00520-013-1891-7","volume":"21","author":"T Godskesen","year":"2013","unstructured":"Godskesen T, Nygren P, Nordin K, Hansson M, Kihlbom U. Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation. Support Care Cancer. 2013;21:3137\u201342.","journal-title":"Support Care Cancer"},{"issue":"2","key":"1443_CR42","first-page":"302","volume":"13","author":"S Henrard","year":"2015","unstructured":"Henrard S, Speybroeck N, Hermans C. Participation of people with haemophilia in clinical trials of new treatments: an investigation of patients' motivations and existing barriers. Blood Transfus. 2015;13(2):302\u20139.","journal-title":"Blood Transfus"},{"issue":"2","key":"1443_CR43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1740774517751118","volume":"15","author":"HL Peay","year":"2018","unstructured":"Peay HL, Biesecker BB, Wilfond BS, et al. Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders. Clin Trials. 2018;15(2):139\u201348.","journal-title":"Clin Trials"},{"key":"1443_CR44","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s10897-017-0170-z","volume":"27","author":"HM Rocha","year":"2018","unstructured":"Rocha HM, Savatt JM, Riggs ER, Wagner JK, Faucett WA, Martin CL. Incorporating social media into your support tool box: points to consider from genetics-based communities. J Genet Couns. 2018;27:470\u201380.","journal-title":"J Genet Couns"},{"issue":"1","key":"1443_CR45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61.","journal-title":"Orphanet J Rare Dis"},{"key":"1443_CR46","doi-asserted-by":"publisher","unstructured":"Togo CCG, Zidorio APC, Goncalves VSS, et al. Quality of life in people with epidermolysis bullosa: a systematic review. Qual Life Res. 2020. https:\/\/doi.org\/10.1007\/s11136-020-02495-5.","DOI":"10.1007\/s11136-020-02495-5"},{"issue":"3","key":"1443_CR47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0167-6296(99)00037-5","volume":"19","author":"W Groot","year":"2000","unstructured":"Groot W. Adaptation and scale of reference bias in self-assessments of quality of life. J Health Econ. 2000;19(3):403\u201320.","journal-title":"J Health Econ"},{"issue":"8","key":"1443_CR48","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0277-9536(98)00411-0","volume":"48","author":"GL Albrecht","year":"1999","unstructured":"Albrecht GL, Devlieger PJ. The disability paradox: high quality of life against all odds. Soc Sci Med. 1999;48(8):977\u201388.","journal-title":"Soc Sci Med"},{"key":"1443_CR49","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1111\/jdv.15371","volume":"33","author":"S D\u0103nescu","year":"2019","unstructured":"D\u0103nescu S, S\u0103l\u0103v\u0103stru C, Sendrea A, et al. Correlation between disease severity and quality of life in patients with epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2019;33:e217\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1443_CR50","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/bjd.16350","volume":"178","author":"AL Bruckner","year":"2018","unstructured":"Bruckner AL, Fairclough DL, Feinstein JA, et al. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB). Br J Dermatol. 2018;178(5):1128\u201334.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1443_CR51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1443_CR52","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1365-2133.2009.09347.x","volume":"161","author":"JW Frew","year":"2009","unstructured":"Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol. 2009;161(6):1323\u201330.","journal-title":"Br J Dermatol"},{"key":"1443_CR53","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2230.2002.01121.x","volume":"27","author":"HM Horn","year":"2002","unstructured":"Horn HM, Tidman MJ. Quality of life in epidermolysis bullosa. Clin Exp Dermatol. 2002;27:707\u201310.","journal-title":"Clin Exp Dermatol"},{"key":"1443_CR54","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1365-2133.2009.09306.x","volume":"161","author":"S Tabolli","year":"2009","unstructured":"Tabolli S, Sampogna F, Di Pietro C, et al. Quality of life in patients with epidermolysis bullosa. Br J Dermatol. 2009;161:867\u201377.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1443_CR55","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/jech.2004.021204","volume":"59","author":"A Bowling","year":"2005","unstructured":"Bowling A. Just one question: if one question works, why ask several? J Epidemiol Community Health. 2005;59(5):342\u20135.","journal-title":"J Epidemiol Community Health"},{"key":"1443_CR56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/pde.12317","volume":"32","author":"A Schwieger-Briel","year":"2015","unstructured":"Schwieger-Briel A, Chakkittakandiyil A, Lara-Corrales I, et al. Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool. Pediatr Dermatol. 2015;32:41\u201352.","journal-title":"Pediatr Dermatol"},{"key":"1443_CR57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2013.09.041","volume":"70","author":"CCH Loh","year":"2014","unstructured":"Loh CCH, Kim J, Su JC, et al. Development, reliability, and validity of a novel Epidermolysis Bullosa disease activity and scarring index (EBDASI). J Am Acad Dermatol. 2014;70:89\u201397.","journal-title":"J Am Acad Dermatol"},{"key":"1443_CR58","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1365-2133.2009.09041.x","volume":"160","author":"C Moss","year":"2009","unstructured":"Moss C, Wong A, Davies P. The Birmingham Epidermolysis Bullosa severity score: development and validation. Br J Dermatol. 2009;160:1057\u201365.","journal-title":"Br J Dermatol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01443-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:14:51Z","timestamp":1625876091000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01443-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01443-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by an institutional review board of the patient advocacy group DEBRA Austria.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}